Although previous studies had noted that breast cancers arising in PALB2 mutation carriers were more likely to be ER-/PR-/HER2- (triple negative) [61,63-65], the triple-negative receptor status was not observed in our study. This evidence concerns the gene ERBB2 and breast carcinoma.